Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
drug-drug
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "drug-drug" in MCE Product Catalog:
Cat. No.: HY-168046
CAS No.: 2542029-03-6
Target:
Research Areas:
ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC50 of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .
Cat. No.: HY-176515
CAS No.: 3118400-26-0
Synonyms: Ciprofol Glucuronide
Target:
Research Areas:
Cipepofol glucuronide (Ciprofol Glucuronide) (M4) is a glucuronide metabolite of Ciprofol (HY-116152). Cipepofol glucuronide has no significant inhibitory activity toward P450s and UDP-glucuronosyltransferases (UGTs), and it has a lower risk of acting as a perpetrator for drug-drug interactions (DDIs). Cipepofol glucuronide can be used for anesthesia research .
Cat. No.: HY-W064918
CAS No.: 1473450-60-0
NITD-304 is an orally active anti-tuberculosis agent. NITD-304 exerts inhibitory and bactericidal activities gainst Mycobacterium tuberculosis and multidrug-resistant Mycobacterium tuberculosis. NITD-304 inhibits mycobacterial cell wall biosynthesis and demonstrates synergistic or additive growth inhibitory activity with select antibacterial agents. NITD-304 shows low risk of cardiotoxicity and drug-drug interactions, with no inhibition of major cytochrome P-450 enzymes or hERG channel. NITD-304 can be used for the research of tuberculosis and multidrug-resistant tuberculosis .
Cat. No.: HY-172811
CAS No.: 2969158-02-7
Target:
Research Areas:
DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S reduces blood glucose levels and suppresses appetite, demonstrates minimal safety risks including low hERG channel inhibition and no significant off-target toxicity, and mitigates drug-drug interaction risk. DA-302168S can be used for the research of type 2 diabetes and obesity .
Cat. No.: HY-169320
CAS No.: 2998548-72-2
Research Areas:
SJPYT-328 is a PXR agonsit. PXR plays a major role in drug metabolism and drug-drug interactions .
Cat. No.: HY-D2921
CAS No.: 1622162-61-1
Cat. No.: HY-172808
CAS No.: 2836313-12-1
Target:
Research Areas:
BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD). BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding .
Cat. No.: HY-181151
CAS No.: 2457357-91-2
Target:
Research Areas:
DLX48 is a LeuBAT (Δ13 mutant) transporter inhibitor that binds to the transporter’s active site. DLX48 can crosses the blood-brain barrier, and has a lower risk of cytochrome P450-related drug-drug interactions. DLX48 can be used for the research of major depressive disorder .
Cat. No.: HY-D3433
CAS No.: 222159-75-3
Synonyms: CDCSF
Target:
Research Areas:
5-Carboxy-2′,7′-dichlorosulfonefluorescein (CDCSF) is a fluorescein derivative-based fluorescent probe. 5-Carboxy-2′,7′-dichlorosulfonefluorescein serves as a fluorescent substrate for the organic anion transporting polypeptide OATP2B1, and is specifically recognized and transported into cells by OATP2B1 under acidic pH conditions, making it suitable for in vitro high-throughput screening of drug-drug interactions (DDI) and food-drug interactions (FDI) (Ex/Em = 485/535 nm) .
Cat. No.: HY-L169
706 compounds
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.
MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
